RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial

BACKGROUND: Glypican-3 (GPC3) is a well-characterized hepatocellular carcinoma (HCC)-associated antigen and a promising target for HCC treatment. CT017 CAR T cells were engineered to co-express CAR-GPC3 and runt-related transcription factor 3 (RUNX3), which triggers CD8(+) T-cell infiltration into t...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Qihan, Zheng, Yi, Fang, Weijia, Zhao, Qingwei, Zhao, Peng, Liu, Lulu, Zhai, You, Tong, Zhou, Zhang, Hangyu, Lin, Meihua, Zhu, Xudong, Wang, Huamao, Wang, Yumeng, Liu, Zhen, Yuan, Daijing, Bao, Xuanwen, Gao, Wanwan, Dai, Xiaomeng, Li, Zonghai, Liang, Tingbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480529/
https://www.ncbi.nlm.nih.gov/pubmed/37680942
http://dx.doi.org/10.1016/j.eclinm.2023.102175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480529/
https://www.ncbi.nlm.nih.gov/pubmed/37680942
http://dx.doi.org/10.1016/j.eclinm.2023.102175

Ejemplares similares